surmount-1 trial tirzepatide weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Shifts in body mass index

They are a sign that your body is adapting to a new metabolic reality, and it needs some support during the transition

Findings: RCTSURMOUNT-MAINTAIN - Tirzepatide for Maintenance of Bodyweight Reduction in Obesity, Lancet (2026) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=378 | length = 112 weeks) in adults with obesity who completed 60 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg once weekly) Treatment: Continue tirzepatide maximum tolerated dose (MTD

A perhaps surprising appearance in the top five focus areas was Prader-Willi syndrome, which is the focus of 56 studies

2025 James R

It sets the boundaries for how the material is purchased, stored, described, and used inside the lab